Investigating Molecular Determinants of Cancer Cell Resistance to Ionizing Radiation Through an Integrative Bioinformatics Approach
Ημερομηνία
2021Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Eradication of cancer cells through exposure to high doses of ionizing radiation (IR) is a widely used therapeutic strategy in the clinical setting. However, in many cases, cancer cells can develop remarkable resistance to radiation. Radioresistance represents a prominent obstacle in the effective treatment of cancer. Therefore, elucidation of the molecular mechanisms and pathways related to radioresistance in cancer cells is of paramount importance. In the present study, an integrative bioinformatics approach was applied to three publicly available RNA sequencing and microarray transcriptome datasets of human cancer cells of different tissue origins treated with ionizing radiation. These data were investigated in order to identify genes with a significantly altered expression between radioresistant and corresponding radiosensitive cancer cells. Through rigorous statistical and biological analyses, 36 genes were identified as potential biomarkers of radioresistance. These genes, which are primarily implicated in DNA damage repair, oxidative stress, cell pro-survival, and apoptotic pathways, could serve as potential diagnostic/prognostic markers cancer cell resistance to radiation treatment, as well as for therapy outcome and cancer patient survival. In addition, our findings could be potentially utilized in the laboratory and clinical setting for enhancing cancer cell susceptibility to radiation therapy protocols. © Copyright © 2021 Toy, Karakülah, Kontou, Alotaibi, Georgakilas and Pavlopoulou.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients
Liontos M., Trigka E.-A., Korkolopoulou P., Tzannis K., Lainakis G., Koutsoukos K., Kostouros E., Lykka M., Papandreou C.N., Karavasilis V., Christodoulou C., Papatsoris A., Skolarikos A., Varkarakis I., Adamakis I., Alamanis C., Stravodimos K., Mitropoulos D., Deliveliotis C., Constantinidis C.A., Saetta A., Patsouris E., Dimopoulos M.Α., Bamias A. (2017)Purpose: To identify prognostic molecular profiles in patients with mRCC treated with sunitinib, we performed immunohistochemical analysis for VEGF and PI3K/Akt/mTOR pathway components. Methods: The immunohistochemical ... -
Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer
Dimitrakopoulos F.-I., Kottorou A., Tzezou A. (2021)Despite the enormous advances during the last three decades, breast cancer continues to be the most frequent type of cancer as well as one of the most frequent cancer-related causes of death in women. Therapeutic management ... -
Istaroxime Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells
Stagno M.J., Zacharopoulou N., Bochem J., Tsapara A., Pelzl L., Al-Maghout T., Kallergi G., Alkahtani S., Alevizopoulos K., Dimas K., Calogeropoulou T., Warmann S.W., Lang F., Schmid E., Stournaras C. (2017)Background/Aims: Istaroxime is a validated inotropic Na + /K + ATPase inhibitor currently in development for the treatment of various cardiac conditions. Recent findings established that this steroidal drug exhibits potent ...

